Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBITDA: 2019-2024

Historic EBITDA for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Dec 2024 value amounting to $145.6 million.

  • Harmony Biosciences Holdings' EBITDA rose 8.88% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year increase of 50.06%. This contributed to the annual value of $145.6 million for FY2024, which is 12.83% up from last year.
  • Harmony Biosciences Holdings' EBITDA amounted to $145.6 million in FY2024, which was up 12.83% from $129.0 million recorded in FY2023.
  • In the past 5 years, Harmony Biosciences Holdings' EBITDA registered a high of $181.3 million during FY2022, and its lowest value of -$36.9 million during FY2020.
  • Its 3-year average for EBITDA is $152.0 million, with a median of $145.6 million in 2024.
  • In the last 5 years, Harmony Biosciences Holdings' EBITDA soared by 424.08% in 2022 and then dropped by 28.85% in 2023.
  • Over the past 5 years, Harmony Biosciences Holdings' EBITDA (Yearly) stood at -$36.9 million in 2020, then skyrocketed by 193.65% to $34.6 million in 2021, then soared by 424.08% to $181.3 million in 2022, then fell by 28.85% to $129.0 million in 2023, then climbed by 12.83% to $145.6 million in 2024.